Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial
Autor: | L. Van Nueten, Y. Lacourciere, Alain Dupont, D. M. Marcadet, J. I. S. Robertson, K. Korlipara, G. Vyssoulis |
---|---|
Přispěvatelé: | Internal Medicine Specializations |
Rok vydání: | 1999 |
Předmět: |
Adult
Male medicine.medical_specialty Nifedipine Adrenergic beta-Antagonists Diastole Vasodilation Blood Pressure Essential hypertension law.invention Nebivolol Orthostatic vital signs Randomized controlled trial Double-Blind Method law Heart Rate Internal medicine Heart rate Medicine Humans Pharmacology (medical) Benzopyrans Antihypertensive Agents Aged Pharmacology business.industry General Medicine Middle Aged medicine.disease Calcium Channel Blockers Treatment Outcome Ethanolamines Hypertension Cardiology Female business medicine.drug |
Zdroj: | Vrije Universiteit Brussel |
ISSN: | 1075-2765 |
Popis: | The efficacy and acceptability of 5 mg nebivolol once daily, a long-acting, vasodilating cardioselective beta blocker that additionally facilitates the L-arginine/nitric oxide system, was assessed in a double-blind, randomized trial in comparison with 20 mg nifedipine retard twice daily in patients with essential hypertension. At 2 weeks of treatment, nebivolol was significantly more effective. Thereafter, both drugs effectively and similarly lowered systolic and diastolic pressures without orthostatic effect. Nebivolol had a trough-to-peak antihypertensive effect ratio of 90%. Nifedipine gave the expected side effects of headache, flushing, and edema. Nebivolol was well tolerated. Nebivolol slightly but significantly lowered heart rate. Neither drug adversely affected plasma levels of lipids. |
Databáze: | OpenAIRE |
Externí odkaz: |